Comparative clinical trial to assess lifespan, metabolic, and quality of life outcomes of weight loss methods in metabolic syndrome
Background
The global prevalence of type 2 diabetes mellitus (T2D) is rising, often complicated by arterial hypertension and obesity, collectively known as metabolic syndrome (MS). Cardiovascular complications are the leading cause of death in MS patients. While objective weight loss is known to improve clinical and laboratory parameters in T2D and hypertension, a comprehensive comparison of different weight loss methods (pharmacologic, surgical, dietetic) on long-term outcomes like lifespan, glycemic control, and quality of life is needed to guide optimal treatment strategies.
Study Design
This open-label, prospective, multicenter, comparative clinical trial will enroll 150 adult patients (aged 35-65 years, BMI ≥27 kg/m2 for Asian populations) with metabolic syndrome. Participants will be distributed into three comparative groups: drug treatment, bariatric surgery, and diet. The study duration is 24 weeks. Primary endpoints include weight loss, fasting blood glucose, blood insulin level, and systolic/diastolic BP. Secondary endpoints will assess blood lipids, heel bone mineral density (HBMD), and ejection fraction (EF). An intention-to-treat analysis will be performed.
Results
As a prospective multicenter clinical study, this trial expects to provide comparative results on various critical parameters. The research aims to evaluate the impact of pharmacological, bariatric, and dietary weight loss methods on life expectancy, glycemic metabolism, lipid metabolism, quality of life, and cost-effectiveness in patients with obesity, T2D, and hypertension. The study will compare changes in primary endpoints such as weight loss, fasting blood glucose, blood insulin level, and systolic/diastolic BP across the three intervention groups. Secondary endpoints, including blood lipids, heel bone mineral density, and ejection fraction, are also expected to show differential responses, providing a holistic view of each method's efficacy. The findings will be disseminated through at least three peer-reviewed articles and/or reviews, and at least one patent for an invention is anticipated.
Key Findings
- Study will compare pharmacologic, surgical, and dietetic weight loss methods.
- Primary endpoints include weight loss, fasting blood glucose, insulin, and blood pressure.
- Secondary endpoints cover blood lipids, bone mineral density, and ejection fraction.
- Expected to provide comparative data on lifespan, glycemic/lipid metabolism, and quality of life.
Why It Matters
This comparative clinical trial protocol is crucial for establishing evidence-based guidelines for metabolic syndrome management. By directly comparing pharmacologic, surgical, and dietetic approaches, the study aims to identify which method offers superior long-term benefits in terms of lifespan, metabolic control, and patient quality of life. The findings will inform clinicians and patients on the most effective and cost-efficient weight loss strategies for T2D and hypertension. This could lead to more personalized treatment plans, potentially optimizing patient outcomes and reducing cardiovascular complications. While the results are pending, the study design itself highlights the need for a comprehensive, head-to-head comparison of current weight loss interventions.
metabolic-syndrome
type-2-diabetes
hypertension
obesity
weight-loss
clinical-trial-protocol